Scientists discuss in "Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer" new findings in prostate cancer. "Prostate cancer cells, like normal prostate epithelial cells, produce high levels of the differentiation marker and serine protease prostate-specific antigen (PSA). PSA is used extensively as a biomarker to screen for prostate cancer, to detect recurrence following local therapies, and to follow response to systemic therapies for metastatic disease," investigators in the United States report. "While much is known about PSA's role as a biomarker, only a relatively few studies address the role played by PSA in the pathobiology of prostate cancer. Autopsy studies have documented that...

In men with nonmetastatic prostate cancer who received androgen deprivation therapy, 70 mg of alendronate once weekly prevented bone mass loss and increased bone mineral density. (CME)
Medscape Medical News